GlassScriptPhysician profile
Laura Martin
NPI 1831489707
$4,000.61
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,124 · 2022: $768 · 2023: $1,416 · 2024: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,927 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,926.66 |
| Education | $182.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $615.32 | 2021-2024 | |
| Janssen Biotech, INC. | $531.60 | 2021-2024 | Erleada, Balversa, Akeega |
| Janssen Scientific Affairs, LLC | $500.00 | 2021 | |
| Merck Sharp & Dohme LLC | $376.79 | 2021-2024 | Keytruda, Welireg, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $272.61 | 2021-2024 | |
| Eisai INC. | $203.28 | 2021-2024 | |
| Dendreon Pharmaceuticals LLC | $168.97 | 2024 | Provenge |
| Medtronic, INC. | $160.98 | 2021-2023 | Interstim |
| E.R. Squibb & Sons, L.L.C. | $152.16 | 2021-2024 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $143.19 | 2022-2024 | Lynparza |
| Novartis Pharmaceuticals Corporation | $140.30 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $128.07 | 2023-2024 | Orgovyx |
| Astellas Pharma US INC | $101.74 | 2021-2023 | |
| Myriad Genetic Laboratories, INC. | $92.61 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $70.48 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $66.28 | 2021 | |
| Progenics Pharmaceuticals, INC. | $58.67 | 2022-2024 | Pylarify |
| Blue Earth Diagnostics | $50.19 | 2022-2024 | |
| Emd Serono, INC. | $50.14 | 2023 | Bavencio |
| Tolmar, INC. | $49.34 | 2023 | |
| Axonics, INC. | $26.32 | 2022-2023 | Axonics |
| Civco Medical Instruments | $25.02 | 2024 | |
| Myovant Sciences INC. | $16.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.